Literature DB >> 29154749

Complications and monitoring of percutaneous renal biopsy - a retrospective study
.

Yvette Feldmann, Klaas Böer, Gunter Wolf, Martin Busch.   

Abstract

BACKGROUND AND AIMS: Percutaneous renal biopsy is a necessary tool to diagnose renal diseases but complications may still occur. The aims of this study were to detect the rate of complications, possible risk factors and to identify the necessity of routine post-biopsy controls at 4 - 6, and 24 hours.
MATERIALS AND METHODS: This single-center retrospective study included 500 consecutive biopsies of native and allograft kidneys performed at the Jena University Hospital.
RESULTS: Major complications occurred in 2.4% of all cases: 9 patients received blood transfusions (1.8%), 2 arterial-venous fistulas (0.4%), 1 angiographic intervention (0.2%), no surgical intervention or death. Minor complications after 24 (4 - 6) hours appeared in 31.8 (41.2)%: 14.8 (11.0)% had hematomas detected by ultrasound (n = 74), 17.0 (30.2)% a reduction of hemoglobin concentration ≥ 1.0 g/dL (n = 85), 4.8 (2.6)% both (n = 24), 1 macrohematuria (0.2%). Systolic blood pressure (≥ 155 mmHg vs. ≤ 126 mmHg, OR 2.007, 95% CI 1.003 - 4.018, p = 0.049) and younger age (per 1 year increase, OR 0.983, 95% CI 0.968 - 0.998, p = 0.027) were associated with the presence of hematoma. Baseline hemoglobin (per increase of 1.6 g/dL, OR 1.499, 95% CI 1.222 - 1.840, p < 0.001) and interstitial fibrosis (≥ 50% vs. ≤ 16%, OR 2.694, 95% CI 1.212 - 5.987, p = 0.015) influenced the finding of a persistent hemoglobin reduction ≥ 1.0 g/dL after 24 hours.
CONCLUSION: The complication rate after renal biopsy is low. Despite the lack of prospective data, our findings suggest that follow-up by a single blood count test combined with ultrasound examination at the day after renal biopsy would be sufficient, at least in the absence of explicit symptoms or risk factors for bleeding.
.

Entities:  

Mesh:

Year:  2018        PMID: 29154749     DOI: 10.5414/CN109223

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

1.  Experience and results after the implementation of a radiology day unit in a reference hospital.

Authors:  Nuria Roson; Andreu Antolin; Richard Mast; Cristina Sanchéz-Tirado; Jesús Griñón; Jordi Andreu; Mercedes Perez Lafuente; Alejandro Tomasello; Manuel Escobar
Journal:  Insights Imaging       Date:  2022-06-29

2.  Nephrologists' Attitudes Toward Native Kidney Biopsy: A Qualitative Study.

Authors:  Afolarin Amodu; Thalia Porteny; Insa M Schmidt; Keren Ladin; Sushrut S Waikar
Journal:  Kidney Med       Date:  2021-09-22

3.  The Tangential Extraperitoneal Retrorenal Approach in Kidney Transplant Biopsy: An Observational Study to Assess Complication and Adequacy Rates.

Authors:  Markus Pirklbauer; Martin Berger; Miro D Boban; Martin Tiefenthaler
Journal:  Transpl Int       Date:  2022-01-13       Impact factor: 3.782

4.  Frequency, Timing, and Prediction of Major Bleeding Complications From Percutaneous Renal Biopsy.

Authors:  Melissa Schorr; Pavel S Roshanov; Matthew A Weir; Andrew A House
Journal:  Can J Kidney Health Dis       Date:  2020-05-25

Review 5.  Urologic Diseases Germane to the Medical Renal Biopsy: Review of a Large Diagnostic Experience in the Context of the Renal Architecture and Its Environs.

Authors:  Stephen M Bonsib
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 3.875

6.  Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases.

Authors:  Tobias Hoffmann; Peter Oelzner; Martin Busch; Marcus Franz; Ulf Teichgräber; Claus Kroegel; Paul Christian Schulze; Gunter Wolf; Alexander Pfeil
Journal:  Diagnostics (Basel)       Date:  2021-12-29

7.  18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation.

Authors:  Felix G Gassert; Johannes Rübenthaler; Clemens C Cyran; Johann S Rink; Vincent Schwarze; Johanna Luitjens; Florian T Gassert; Marcus R Makowski; Stefan O Schoenberg; Marius E Mayerhoefer; Dietmar Tamandl; Matthias F Froelich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-09       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.